Relmada Therapeutics (RLMD) Competitors

Relmada Therapeutics logo
$3.01 -0.60 (-16.62%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 +0.12 (+4.12%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RLMD vs. ANIP, GPCR, OCUL, PCRX, and LBRX

Should you buy Relmada Therapeutics stock or one of its competitors? Relmada Therapeutics's main competitors and comparable companies include ANI Pharmaceuticals (ANIP), Structure Therapeutics (GPCR), Ocular Therapeutix (OCUL), Pacira BioSciences (PCRX), and LB Pharmaceuticals (LBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Relmada Therapeutics compare to ANI Pharmaceuticals?

Relmada Therapeutics (NASDAQ:RLMD) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

ANI Pharmaceuticals has a net margin of 11.22% compared to Relmada Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 28.34% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -38.51% -35.94%
ANI Pharmaceuticals 11.22%28.34%11.18%

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Relmada Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 232.41%. ANI Pharmaceuticals has a consensus target price of $100.00, suggesting a potential upside of 41.06%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
ANI Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

ANI Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
ANI Pharmaceuticals$883.37M1.82$78.34M$5.0214.12

In the previous week, Relmada Therapeutics had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 11 mentions for Relmada Therapeutics and 7 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.61 beat Relmada Therapeutics' score of 0.56 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
ANI Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

ANI Pharmaceuticals beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to Structure Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Relmada Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.12, indicating that its stock price is 212% less volatile than the broader market.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
Structure TherapeuticsN/AN/A-$141.20M-$1.29N/A

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 232.41%. Structure Therapeutics has a consensus target price of $110.91, indicating a potential upside of 497.25%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Structure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

In the previous week, Structure Therapeutics had 8 more articles in the media than Relmada Therapeutics. MarketBeat recorded 19 mentions for Structure Therapeutics and 11 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.56 beat Structure Therapeutics' score of 0.52 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Structure Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Structure Therapeutics' return on equity of -29.18% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -38.51% -35.94%
Structure Therapeutics N/A -29.18%-27.62%

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Structure Therapeutics beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Relmada Therapeutics compare to Ocular Therapeutix?

Relmada Therapeutics (NASDAQ:RLMD) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Ocular Therapeutix had 10 more articles in the media than Relmada Therapeutics. MarketBeat recorded 21 mentions for Ocular Therapeutix and 11 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.56 beat Ocular Therapeutix's score of -0.06 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocular Therapeutix
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Relmada Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -648.64%. Relmada Therapeutics' return on equity of -38.51% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -38.51% -35.94%
Ocular Therapeutix -648.64%-59.95%-46.75%

Relmada Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Relmada Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
Ocular Therapeutix$51.95M25.45-$265.94M-$1.46N/A

Relmada Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 232.41%. Ocular Therapeutix has a consensus target price of $23.83, suggesting a potential upside of 296.56%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Summary

Relmada Therapeutics and Ocular Therapeutix tied by winning 7 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Pacira BioSciences?

Relmada Therapeutics (NASDAQ:RLMD) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Pacira BioSciences has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A
Pacira BioSciences$726.41M2.01$7.03M$0.35104.23

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 232.41%. Pacira BioSciences has a consensus price target of $33.33, suggesting a potential downside of 8.63%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75
Pacira BioSciences
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09

In the previous week, Relmada Therapeutics had 9 more articles in the media than Pacira BioSciences. MarketBeat recorded 11 mentions for Relmada Therapeutics and 2 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.82 beat Relmada Therapeutics' score of 0.56 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacira BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Pacira BioSciences has a net margin of 5.08% compared to Relmada Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 10.82% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -38.51% -35.94%
Pacira BioSciences 5.08%10.82%6.01%

Relmada Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Summary

Pacira BioSciences beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relmada Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

LB Pharmaceuticals has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LB PharmaceuticalsN/AN/A-$25.20M-$4.62N/A
Relmada TherapeuticsN/AN/A-$57.38M-$0.72N/A

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 13 mentions for LB Pharmaceuticals and 11 mentions for Relmada Therapeutics. LB Pharmaceuticals' average media sentiment score of 0.66 beat Relmada Therapeutics' score of 0.56 indicating that LB Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LB Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relmada Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

LB Pharmaceuticals currently has a consensus target price of $57.40, indicating a potential upside of 33.52%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 232.41%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relmada Therapeutics is more favorable than LB Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LB Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.69
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

Relmada Therapeutics' return on equity of -38.51% beat LB Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
LB PharmaceuticalsN/A -39.49% -37.12%
Relmada Therapeutics N/A -38.51%-35.94%

Summary

Relmada Therapeutics beats LB Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RLMD vs. The Competition

MetricRelmada TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$321.08M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-4.1829.4134.1729.85
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book2.555.114.373.66
Net Income-$57.38M$2.88B$3.52B$392.27M
7 Day Performance-29.51%-4.11%-5.47%-4.72%
1 Month Performance-2.90%-5.09%-4.58%-7.14%
1 Year Performance-24.18%-7.45%-1.79%-7.51%

Relmada Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RLMD
Relmada Therapeutics
3.3165 of 5 stars
$3.01
-16.6%
$12.00
+298.7%
-8.6%$321.08MN/AN/A17
ANIP
ANI Pharmaceuticals
3.6471 of 5 stars
$69.09
+1.9%
$100.00
+44.7%
-15.6%$1.59B$883.37M13.80970
GPCR
Structure Therapeutics
2.9622 of 5 stars
$21.25
-0.8%
$110.91
+422.0%
-49.6%$1.50BN/AN/A281
OCUL
Ocular Therapeutix
2.5003 of 5 stars
$6.64
-3.1%
$23.83
+259.2%
-46.8%$1.46B$51.95MN/A325
PCRX
Pacira BioSciences
2.2421 of 5 stars
$36.49
+0.1%
$33.33
-8.6%
+53.4%$1.45B$726.41M104.25829

Related Companies and Tools


This page (NASDAQ:RLMD) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners